PLAB induction in fenretinide-induced apoptosis of ovarian cancer cells occurs via a ROS-dependent mechanism involving ER stress and JNK activation
Authors:
- V. AppiertoVAV. Appierto
- P. TiberioPTP. Tiberio
- M. G. VillaniMVM. G. Villani
- E. CavadiniECE. Cavadini
- F. FormelliFFF. Formelli
- 26 March 2009
- journal article
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 30 (5) , 824-831
Abstract
Fenretinide [N-(4-hydroxyphenyl)-retinamide (4HPR)] is a synthetic retinoid with antitumor activity that induces apoptosis in various types of cancer cell. We showed previously that 4HPR upregulates the proapoptotic gene placental bone morphogenetic protein (PLAB), which is a mediator of 4HPR-induced apoptosis in ovarian cancer cells. Here, we investigated the signaling cascade involving PLAB that mediates the apoptotic effect. In 4HPR-sensitive ovarian cancer cells, 4HPR-induced reactive oxygen species (ROS) are involved in PLAB upregulation and apoptosis, both events abrogated by the antioxidants vitamin C and butylated hydroxyanisole. We analyzed the expression and activation of endoplasmic reticulum (ER) stress-associated molecules and show that 4HPR-induced ER stress is a consequence of ROS generation. Salubrinal, an ER stress inhibitor, abrogated 4HPR-induced PLAB upregulation and protected the cells from apoptosis. Downstream of ROS generation and ER stress, 4HPR activated c-Jun N-terminal kinase (JNK), which was inhibited by vitamin C and salubrinal. The JNK inhibitor SP600125 reduced 4HPR-induced PLAB upregulation, by decreasing PLAB mRNA half-life, and protected the cells from apoptosis. These data indicate that 4HPR-induced PLAB upregulation occurs downstream of a signaling cascade involving ROS generation, ER stress induction and JNK activation and that these steps are mediators of 4HPR-induced apoptosis.Keywords
This publication has 39 references indexed in Scilit:
- Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cellsOncogene, 2007
- Mechanisms of fenretinide-induced apoptosisApoptosis, 2006
- Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancerAnnals of Oncology, 2006
- Changes in gene expression contribute to cancer prevention by COX inhibitorsProgress in Lipid Research, 2005
- Randomized trial of fenretinide (4‐HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: Long‐term resultsInternational Journal of Cancer, 2005
- Effect of Fenretinide on Ovarian Carcinoma OccurrenceGynecologic Oncology, 2002
- The propeptide of macrophage inhibitory cytokine (MIC‐1), a TGF‐β superfamily member, acts as a quality control determinant for correctly folded MIC‐1The EMBO Journal, 2000
- Randomized Trial of Fenretinide to Prevent Second Breast Malignancy in Women With Early Breast CancerJNCI: Journal of the National Cancer Institute, 1999
- Retinoid-induced apoptosis in normal and neoplastic tissuesCell Death & Differentiation, 1998
- Bioactivities of N‐(4‐hydroxyphenyl) retinamide and retinoyl β‐glucuronideThe FASEB Journal, 1996